Catalyst Repository | Gemini Therapeutics Inc. Common Stock

Gemini Therapeutics Inc. Common Stock

(NASDAQ:GMTX)

Description

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.

GMTX Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$1.5400
Previous Close Volume
24650


Latest News